Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data BIOHARVEST SCIENCES INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
12.7
25.2
34.5
Cost of revenue
7.04
11.2
14
Gross profit
5.63
13.9
20.5
Research and development
3.37
4.8
5.31
Selling and marketing
7.75
11.7
15.8
Operating expenses
15.6
20.9
26.1
Operating income
-9.97
-6.99
-5.58
Pre-tax income
-12.6
-12.9
-11.1
Income tax
0
-0.01
-0.08
Net income
-12.6
-12.9
-11.1
EBITDA
-9.13
-5.74
-3.95
EPS, basic
-0.93
-0.80
-0.60
EPS, diluted
-0.93
-0.80
-0.60
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
5.36
2.39
23
Receivables
0.81
1.12
1.98
Inventory
2.47
3.66
4.56
Total current assets
9.05
7.86
30.5
Property, plant and equipment
3.93
7.75
8.33
Lease right-of-use assets
1.85
9.02
8.41
Total assets
15
25
47.7
Accounts payable
1.78
3.53
2.63
Accrued liabilities
0.46
0.4
0.39
Short-term debt
0
3.91
0.15
Total current liabilities
26.5
14.3
7.68
Other non-current liabilities
1.96
0.27
1.98
Total liabilities
29.9
23.7
22.2
Paid-in capital
68.7
97.7
133
Retained earnings
-83.5
-96.4
-108
Shareholders' equity
-14.9
1.33
25.4
Total equity
-14.9
1.33
25.4
Total liabilities and equity
15
25
47.7
Cash flow statement
FY2024
FY2024
FY2025
Net income
-12.6
-12.9
-11.1
Depreciation and amortization
0.84
1.25
1.62
Stock-based compensation
0.56
0.6
Deferred income tax
0
0
0
Change in receivables
-0.26
-0.31
-0.87
Change in inventory
-1.09
-1.19
-0.9
Cash from operations
-8.52
-6.68
-7.23
Capital expenditures
-1.47
-2.84
-2.36
Cash from investing
-1.47
-3.03
-2.37
Stock issued
0
0
18.3
Cash from financing
13.6
6.78
30.2
Net change in cash
3.56
-2.93
20.6
Free cash flow
-10
-9.52
-9.58
Interest paid
0.53
0
Income taxes paid
0.05
0.04
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.46 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
59.3%
Gross profit / revenue.
Operating margin
-16.2%
Operating income / revenue.
EBITDA margin
-11.4%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-32.0%
Pre-tax income / revenue.
Net margin
-32.3%
Net income / revenue.
FCF margin
-27.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-20.9%
Cash from operations / revenue.
Return on equity (ROE)
-83.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-30.6%
Net income / average total assets.
Return on invested capital (ROIC)
-646.3%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
15.4%
Research and development expense / revenue.
Capex / revenue
6.8%
Capital expenditures / revenue.
D&A / revenue
4.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
37.0%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
46.9%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
1,813.0%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
90.7%
Total assets vs the same period a year earlier. Only from a positive base.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.97x
Current assets / current liabilities.
Quick ratio
3.25x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.00x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.60
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.60
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$33.1M
Share price x shares outstanding.
Enterprise value
$10.1M
Market cap + total debt - cash - short-term investments.
P/S
0.96x
Market cap / revenue.
P/B
1.30x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.30x
Market cap / tangible book value, when positive.
EV/Sales
0.29x
Enterprise value / revenue.
FCF yield
-28.9%
Free cash flow / market cap.
Earnings yield
-33.6%
Net income / market cap (the inverse of P/E).
What was BIOHARVEST SCIENCES INC.'s revenue in fiscal 2025?
BIOHARVEST SCIENCES INC. reported revenue of $34.5M for fiscal 2025, 37% higher than the year before.
Was BIOHARVEST SCIENCES INC. profitable in fiscal 2025?
No. It reported a net loss of $11.1M.
How much free cash flow did BIOHARVEST SCIENCES INC. generate in fiscal 2025?
Cash from operations of $7.2M minus capital expenditures of $2.4M left free cash flow of -$9.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.